Cost-Effectiveness Of The SQ^® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective

References

• Bergmann KC, Heinrich J, Niemann H. Current status of allergy prevalence in Germany: position paper of the Environmental Medicine Commission of the Robert Koch Institute. Allergo J Int. 2016;25:6–10. doi:10.1007/s40629-016-0092-627069844
   PubMedGoogle Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758–764. doi:10.1183/09031936.04.0001390415516669
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. doi:10.1111/j.1398-9995.2007.01620.x18331513
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147–S334. doi:10.1067/mai.2001.11889111707753
   PubMed Web of Science ®Google Scholar
• Burgess JA, Walters EH, Byrnes GB, et al Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120:863–869. doi:10.1016/j.jaci.2007.07.02017825896
   PubMed Web of Science ®Google Scholar
• Canonica GW. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62 supp:17–25. doi:10.1111/j.1398-9995.2007.01549.x
   Web of Science ®Google Scholar
• Cardell LO, Olsson P, Andersson M, et al TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. doi:10.1038/npjpcrm.2015.8226845513
   PubMed Web of Science ®Google Scholar
• Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7:12. doi:10.1186/1939-4551-7-1224940476
   PubMedGoogle Scholar
• Price D, Scadding G, Ryan D, et al The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39. doi:10.1186/s13601-015-0083-626583068
   PubMedGoogle Scholar
• Valovirta E, Petersen TH, Piotrowska T, et al Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141:529–538. doi:10.1016/j.jaci.2017.06.01428689794
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Rep. CHMP/EWP/18504/2006. London, UK: European Medicines Agency; 2008.
   Google Scholar
• Schmitt J, Schwarz K, Stadler E, Wustenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study. J Allergy Clin Immunol. 2015;136:1511–1516. doi:10.1016/j.jaci.2015.07.03826371838
   PubMed Web of Science ®Google Scholar
• Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165–177. doi:10.1111/all.1321328561266
   PubMed Web of Science ®Google Scholar
• GINA Board of Directors and Committees. Global Strategy for Asthma Management and Prevention. Asthma management and prevention for adults and children over 5 years: a pocket guide for healthcare professionals. 2019 Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf Accessed 530, 2019.
   Google Scholar
• Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2015;60:350–353. doi:10.1111/j.1398-9995.2005.00751.x
   Web of Science ®Google Scholar
• Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117:158–162. doi:10.1016/j.jaci.2005.09.04716387600
   PubMed Web of Science ®Google Scholar
• Colas C, Brosa M, Anton E, et al. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study. Allergy. 2017;72:959–966. doi:10.1111/all.1309927886391
   PubMed Web of Science ®Google Scholar
• Petersen KD, Kronborg C, Gyrd-Hansen D, Dahl R, Larsen JN, Lowenstein H. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy. 2008;3:284–291. doi:10.1111/j.1398-9995.2007.01583.x
   Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;2012(129):717–725. doi:10.1016/j.jaci.2011.12.973
   Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–948. doi:10.1111/j.1398-9995.2007.01451.x17620073
   PubMed Web of Science ®Google Scholar
• Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy. 2007;37:772–779. doi:10.1111/j.1365-2222.2007.02706.x17456225
   PubMed Web of Science ®Google Scholar
• Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children. Clinicoecon Outcomes Res. 2014;6:187–196.24812522
   PubMedGoogle Scholar
• Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–256. doi:10.1067/mai.2002.12131711842293
   PubMed Web of Science ®Google Scholar
• Domdey A, Grand TS, Elliot L, Tesch F, Schmitt J, Küster D. Costs and resource use in allergic rhinitis. Allergy. 2018;73(S105):471. doi:10.1111/all.13244
   Web of Science ®Google Scholar
• Retzler J, Grand TS, Domdey A, Smith A, Romano RM. Utility elicitation in adults and children for allergic rhinoconjunctivitis and associated health states. Qual Life Res. 2018;27:2383–2391. doi:10.1007/s11136-018-1910-829948599
   PubMedGoogle Scholar
• Janssen MF, Szende A, Cabases J, Ramos-Goni JM, Vilagut G, Konig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2018.
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York, UK: Centre for Health Economics; 1999.
   Google Scholar
• Institute for Quality and Efficiency in Health Care. General Methods for the Assessment of the Relation of Benefits to Costs. Cologne, Germany; 2009 Available from: https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf Accessed October 22, 2019.
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. London, UK; 2013 Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 Accessed 516, 2019.
   Google Scholar
• OANDA Corporation. OANDA FX Rate® GBP: EUR exchange rate. Available from: https://www1.oanda.com/fx-for-business/exchange-rates-api Accessed 620, 2019.
   Google Scholar
• Mathes T, Jacobs E, Morfeld JC, Pieper D. Methods of international health technology assessment agencies for economic evaluations–a comparative analysis. BMC Health Serv Res. 2013;13:371. doi:10.1186/1472-6963-13-43824079858
   PubMed Web of Science ®Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798. doi:10.1111/all.1331728940458
   PubMed Web of Science ®Google Scholar
• Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006;61(2):181–184. doi:10.1111/j.1398-9995.2006.00959.x16409193
   PubMedGoogle Scholar
• Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61(2):185–190. doi:10.1111/j.1398-9995.2005.00949.x16409194
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, et al Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121(2):512–518.e2. doi:10.1016/j.jaci.2007.10.03918155284
   PubMed Web of Science ®Google Scholar
• Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–241. doi:10.1016/j.jaip.2013.03.01324565479
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Allergol Int. 2018;67(3):301–308. doi:10.1016/j.alit.2018.03.00829759659
   PubMed Web of Science ®Google Scholar
• Staloral^® Monograph. 7268-3. 6 2011.
   Google Scholar
• GRAZAX^® Summary of Product Characteristics. 6 2018.
   Google Scholar
• Demoly P, Passalacqua G, Calderon MA, Yalaoui T. Choosing the optimal dose in sublingual immunotherapy: rationale for the 300 index of reactivity dose. Clin Transl Allergy. 2015;5:44. doi:10.1186/s13601-015-0088-126702353
   PubMed Web of Science ®Google Scholar
• Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008;63(12):1624–1629. doi:10.1111/j.1398-9995.2008.01743.x19032235
   PubMed Web of Science ®Google Scholar
• Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med. 2007;101(9):1885–1894. doi:10.1016/j.rmed.2007.05.00317611095
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733–743. doi:10.1177/0272989X1245457922990088
   PubMed Web of Science ®Google Scholar
• Richter AK, Klimek L, Merk HF, et al. Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. Eur J Health Econ. 2018;19(9):1229–1242. doi:10.1007/s10198-018-0970-629574666
   PubMedGoogle Scholar